May 27, 2026
At Mayo Clinic, decisions about vestibular schwannoma management are informed by deep clinical experience and patients' individual needs. Multidisciplinary specialists take time to thoroughly assess patients and outline treatment options, without bias toward a single approach.
"The symptomatology of vestibular schwannomas can be quite variable, and people have different priorities in terms of their hoped-for outcomes," says Michael J. Link, M.D., a neurosurgeon at Mayo Clinic in Rochester, Minnesota. "It's not a matter of a patient just getting a diagnosis and then having a specific treatment."
Otolaryngologists provide critical expertise. "Vestibular schwannomas and associated treatment may cause significant problems with hearing, balance and the facial nerve. Treating the side effects, not just the tumor itself, is beneficial," says Matthew L. Carlson, M.D., M.B.A., an otolaryngologist at Mayo Clinic's campus in Minnesota. "ENT and Neurosurgery each bring a little different perspective. Together, we can provide patients with the best options for treatment."
Quality of life is a key consideration. To date, research has found that the type of treatment makes little difference in outcomes for patients with small- to medium-sized tumors. To learn more, Mayo Clinic physician-researchers have developed a more detailed patient survey for people with vestibular schwannomas.
"We want to see how these tumors impact patients beyond the usual issues — to get to the bottom of the best strategy for each patient," Dr. Link says. "That's ultimately what patients want to know most."
Specialized care for vestibular schwannomas is available across the enterprise.
Tumor size and treatment options
Vestibular schwannomas — the preferred term for acoustic neuromas — are often considered rare. But their prevalence is rising, due to sensitive diagnostic imaging. Every year, Mayo Clinic specialists care for about 1,400 people with these tumors.
Treatment choices include observation with regular scanning, radiosurgery or microsurgery. Dr. Link notes that just under half of patients with vestibular schwannomas seen at Mayo Clinic are observed and scanned, with treatment for the remainder split between radiosurgery and microsurgery.
Tumors measuring 2 millimeters or less are generally asymptomatic and usually monitored. Tumors measuring 3 to 4 centimeters typically require surgery. "Between those sizes, the decision-making is pretty nuanced," Dr. Carlson says. "The most important considerations are patient symptoms, patient preferences and tumor size."
Tumor observation means lifelong MRI scans to identify tumor growth. Mayo Clinic's subspecialized neuroradiologists use advanced methods, including volumetric measurements of tumors. "Volumetric analysis can detect what might not be readily evident by visual examination of the MRI," says Jack I. Lane, M.D., a neuroradiologist at Mayo Clinic's campus in Minnesota. "Vestibular schwannomas can have highly irregular shapes, such that a 2- or 3-millimeter increase in linear diameter can result in a 50% to 80% change in total tumor volume, which would be an indication that treatment is needed."
"We want to see how these tumors impact patients beyond the usual issues — to get to the bottom of the best strategy for each patient."
Deciding when to treat small- to medium-sized tumors requires balancing risks and benefits. Treating small tumors risks near-term hearing loss. But observation risks critical hearing loss within a decade and other complications. Dr. Carlson notes that most people diagnosed with vestibular schwannomas are in their 50s. He suggests that, rather than viewing hearing preservation as a binary outcome — "preserved" or "not preserved" — clinicians consider which treatment provides the most time with good function.
"Preserving hearing function for five or 10 years — even if it inevitably goes away for many people — is probably useful. With a small tumor, we try to preserve hearing as long as we can," Dr. Calrson says.
Once tumors are medium- to large-sized, the primary goal is to provide a single treatment — radiosurgery or microsurgery — that best preserves quality of life.
Mayo Clinic's preferred method of radiosurgery for vestibular schwannomas is Gamma Knife stereotactic radiosurgery (SRS). In a study published in the Journal of Neurosurgery, Mayo Clinic researchers found that SRS demonstrated durable tumor control through 15 years of follow-up in 91% of patients studied. "We also observed low complication rates in our large study cohort, which underscores the utility of SRS for initial tumor management," Dr. Carlson says.
Previous Mayo Clinic research outlined a size threshold for performing microsurgery: between 14 and 20 millimeters of cerebellopontine angle extension. Above that cutoff, risks accelerate for incomplete resection, facial nerve paralysis and loss of serviceable hearing. That study also was published in the Journal of Neurosurgery.
"It's important to manage patients' expectations," Dr. Link says. "Unfortunately, treating the tumor doesn't improve all symptoms, including bringing back hearing. But we can help patients cope with remaining symptoms, such as improving balance."
Understanding quality of life
Mayo Clinic's new patient survey — which has been translated into 15 languages — covers concerns less frequently discussed. "For example, we go into greater depth about pain and dizziness," Dr. Link says. "Over the years we've also found that patients often say they feel mentally foggy. That hasn't been examined in other surveys, and it can affect whether people can continue doing their occupations."
Concern for patients is the cornerstone of Mayo Clinic's approach. Neurosurgeons and ENT surgeons are highly subspecialized, focusing on just a few conditions. That level of experience helps ensure optimal care.
"Our goal is to give patients world-class care for this diagnosis," Dr. Link says. "We want them to feel confident that their tumors are being managed appropriately, so they can get on with their lives with as minimal impact as possible."
For more information
Marinelli JP, et al. Long-term tumor control after Gamma Knife radiosurgery for sporadic vestibular schwannoma. Journal of Neurosurgery. 2026;144:965.
Macielak RJ, et al. Defining clinically significant tumor size in vestibular schwannoma to inform timing of microsurgery during wait-and-scan management: Moving beyond minimal detectable growth. Journal of Neurosurgery. 2021;136:1289.
Refer a patient to Mayo Clinic.